Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.
about
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerBreast cancer attributable costs in Germany: a top-down approach based on sickness funds dataExemestane in the adjuvant treatment of breast cancer in postmenopausal women.Cost-utility analyses of drug therapies in breast cancer: a systematic review.
P2860
Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@ast
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@en
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@nl
type
label
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@ast
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@en
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@nl
prefLabel
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@ast
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@en
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@nl
P2093
P2860
P356
P1433
P1476
Cost Effectiveness of Exemesta ...... arly Breast Cancer in Germany.
@en
P2093
Johann-Matthias von der Schulenburg
Sebastian Braun
Thomas Menschik
Thomas Mittendorf
Wolfgang Greiner
P2860
P304
P356
10.1159/000255840
P577
2009-12-11T00:00:00Z